Contralateral breast cancer in BRCA1/BRCA2 mutation carriers: The story of the other side

Journal of Clinical Oncology

Volumn 27, Issue 35, 2009, Pages 5862-5864

  Garber, Judy E ^a   Golshan, Mehra ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; BRCA1 PROTEIN, HUMAN; BRCA2 PROTEIN, HUMAN;

BREAST CANCER; CANCER DIAGNOSIS; CANCER RISK; EDITORIAL; GENE IDENTIFICATION; GENE MUTATION; GENETIC SUSCEPTIBILITY; HETEROZYGOTE; HUMAN; MASTECTOMY; OVARY CANCER; PARTIAL MASTECTOMY; PRIORITY JOURNAL; RISK REDUCTION; AGE; BREAST TUMOR; FEMALE; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION; GENETICS; MUTATION; NOTE; PATHOLOGY; PATIENT SELECTION; PEDIGREE; PERSONALIZED MEDICINE; RISK ASSESSMENT; RISK FACTOR; SECOND CANCER; TIME; TREATMENT OUTCOME;

AGE FACTORS; BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INDIVIDUALIZED MEDICINE; MUTATION; NEOPLASMS, SECOND PRIMARY; PATIENT SELECTION; PEDIGREE; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 73349130020     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2009.25.1652     Document Type: Editorial

References (15)

1. Tutt A, Robson M, Garber J, et al: Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer. J Clin Oncol 27:7s, 2009 (suppl; abstr CRA501)
2. Audeh M, Penson R, Friedlander M, et al: Phase II trial of the oral PARP inhibitor olaparib (AZD2281) in BRCA-deficient advanced ovarian cancer. J Clin Oncol 27:274s, 2007 (suppl; abstr 5500)
3. Gronwald J, Byrski T, Huzarski T, et al: Neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients. J Clin Oncol 27:7s, 2009 (suppl; abstr 502)
4. Haffty BG, Harrold E, Khan AJ, et al: Outcome of conservatively managed early-onset breast cancer by BRCA1/2 status. Lancet 359:1471-1477, 2002
5. Pierce LJ, Levin AM, Rebbeck TR, et al: Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. J Clin Oncol 24:2437-2443, 2006
6. Begg CB, Haile RW, Borg A, et al: Variation of breast cancer risk among BRCA1/2 carriers. JAMA 299:194-201, 2008
7. Metcalfe K, Lynch HT, Ghadirian P, et al: Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 22:2328-2335, 2004
8. Schwartz MD, Lerman C, Brogan B, et al: Utilization of BRCA1/BRCA2 mutation testing in newly diagnosed breast cancer patients. Cancer Epidemiol Biomarkers Prev 14:1003-1007, 2005
9. Tercyak KP, Peshkin BN, Brogan BM, et al: Quality of life after contralateral prophylactic mastectomy in newly diagnosed high-risk breast cancer patients who underwent BRCA1/2 gene testing. J Clin Oncol 25:285-291, 2007
10. Palomares MR, Paz B, Weitzel JN: Genetic cancer risk assessment in the newly diagnosed breast cancer patient is useful and possible in practice. J Clin Oncol 23:3165-3166, 2005; author reply 3166-3167, 2005
11. Mai PL, Lagos VI, Palomares MR, et al: Contralateral risk-reducing mastectomy in young breast cancer patients with and without genetic cancer risk assessment. Ann Surg Oncol 15:3415-3421, 2008
12. Graeser M, Engel C, Rhiem K, et al: Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 27:5887-5892, 2009
13. Gao X, Fisher SG, Emami B: Risk of second primary cancer in the contralateral breast in women treated for early-stage breast cancer: A population-based study. Int J Radiat Oncol Biol Phys 56:1038-1045, 2003
14. Recht A: Contralateral prophylactic mastectomy: Caveat emptor. J Clin Oncol 27:1347-1349, 2009
15. Tuttle TM, Habermann EB, Grund EH, et al: Increasing use of contralateral prophylactic mastectomy for breast cancer patients: A trend toward more aggressive surgical treatment. J Clin Oncol 25:5203-5209, 2007